TGTX - ティ―ジ―・セラピュ―ティクス （TG Therapeutics Inc.） ティ―ジ―・セラピュ―ティクスTGTXのチャート
TGTXの企業情報
| symbol | TGTx |
|---|---|
| 会社名 | TG Therapeutics Inc （ティ―ジ―・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 TG･セラピューティクス（TG Therapeutics Inc.）はB細胞悪性腫瘍及び自己免疫疾患治療薬の買収・開発・商品化に焦点を当てるバイオ医薬品会社である。同社は、血液悪性腫瘍を対象とする2つの治療法を持っている。TG-1101（ウブリツキシマブ）は、成熟Bリンパ球で検出されたCD20抗原における特異的エピトープを対象とする糖鎖工学処理モノクローナル抗体である。同社はまた、経口投与可能なPI3Kデルタ阻害剤であるTGR-1202を開発している。TG-1101とTGR-1202は、血液悪性腫瘍患者を対象として臨床開発中にある。同社はまた、臨床開発にあるIRAK4（インターロイキン-1受容体関連キナーゼ4）の阻害剤を開発するための前臨床プログラム、並びに抗PD-L1・抗グルココルチコイド誘導腫瘍壊死因子受容体（GITR）抗体を開発するための抗体研究プログラムを有する。 ティ―ジ―・セラピュ―ティクスは、米国のバイオ製薬会社。癌やその他の治療のための医薬製品の買収、開発、商業化に焦点を当てるほかB細胞悪性腫瘍および自己免疫疾患のための新規な治療法を開発する。開発製品は、｢TG-1101｣糖操作モノクロ―ナル抗体、｢TGR-1202｣経口投与可能なデルタ阻害剤、｢AST-726｣がある。 TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. |
| 本社所在地 | 2 Gansevoort Street 9th Floor New York NY 10014 USA |
| 代表者氏名 | Michael S. Weiss マイケル・S・ワイス |
| 代表者役職名 | Executive Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 212-554-4484 |
| 設立年月日 | 34090 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 75人 |
| url | www.tgtherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tgtx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -148.45970 |
| 終値（lastsale） | 5.27 |
| 時価総額（marketcap） | 436454064.16 |
| 時価総額 | 時価総額（百万ドル） 444.73590 |
| 売上高 | 売上高（百万ドル） 0.15220 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 318.70090 |
| 当期純利益 | 当期純利益（百万ドル） -148.06640 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 TG Therapeutics Inc revenues remained flat at $76K. Net loss increased 53% to $85.7M. Revenues reflect market conditions. Higher net loss reflects Other research and development increase of 46% to $67M (expense) Noncash compensation increase from $3.9M to $7.9M (expense) Other general and administrative increase of 54% to $4.4M (expense). |
TGTXのテクニカル分析
TGTXのニュース
TG Therapeutics, Inc. (TGTX) Q4 2022 Earnings Call Transcript 2023/02/28 19:06:10 Seeking Alpha
TG Therapeutics, Inc. (NASDAQ:NASDAQ:TGTX) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsJenna Bosco – Investor RelationsMichael Weiss – Chairman and…
TG Therapeutics GAAP EPS of -$0.39 misses by $0.14, revenue of $0.08M misses by $1.52M 2023/02/28 12:32:02 Seeking Alpha
TG Therapeutics press release (TGTX): Q4 GAAP EPS of -$0.39 misses by $0.14.Revenue of $0.08M (-96.6% Y/Y) misses by $1.52M."We anticipate that our cash, cash equivalents and…
TG Therapeutics Q4 2022 Earnings Preview 2023/02/27 22:55:08 Seeking Alpha
TG Therapeutics (TGTX) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open.The consensus EPS Estimate is -$0.26 (vs
Analysts Provide Insight Into TG Therapeutics Inc.’s (TGTX) Potential. 2023/02/25 18:00:00 Stocks Register
TG Therapeutics Inc. (NASDAQ:TGTX) price on Friday, February 24, fall -4.56% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $15.70. A look at the stock’s price movement, the close in the last trading session was $16.45, moving within a range at $15.62 and $16.2324. The beta value … Analysts Provide Insight Into TG Therapeutics Inc.’s (TGTX) Potential. Read More »
Drawing stocks: TG Therapeutics, Inc. (NASDAQ:TGTX -4.56%), Owlet, Inc. (NYSE:OWLT 5.79%) 2023/02/25 12:39:50 Stock Equity
TGTX has seen its SMA50 which is now 18.08%. In looking the SMA 200 we see that the stock has seen a 96.36%. OWLT has seen its SMA50 which is … The post Drawing stocks: TG Therapeutics, Inc. (NASDAQ:TGTX -4.56%), Owlet, Inc. (NYSE:OWLT 5.79%) appeared first on Stocks Equity .
TG Therapeutics slips on concerns over FDA probe on cancer medicine 2022/02/03 15:22:22 Seeking Alpha
TG Therapeutics <> is trading lower after the FDA announced an ongoing investigation over the increased risk of death related to the companys cancer medicine
TG Therapeutics Inc Shares Close the Week 40.9% Lower - Weekly Wrap 2022/01/28 22:45:23 Kwhen Finance
TG Therapeutics Inc (TGTX) shares closed this week 40.9% lower than it did at the end of last week. The stock is currently down 56.5% year-to-date, down 82.2% over the past 12 months, and up 74.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Shares traded as high as $15.26 and as low as $8.04 this week.Trading volume this week was 321.4% higher than the 10-day average and 584.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 175.7% The company's stock price performance over the past 12 months lags the peer average by 192.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
64 Biggest Movers From Yesterday 2022/01/28 09:59:13 Benzinga
Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human Imaging Limited (NASDAQ: AHI ) fell 33.8% to settle at $1.82. Advanced Human Imaging recently signed partnership with Activate Health OÜ. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) dropped 33.6% to close at $0.6280.
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold On Blood Cancer Trials 2022/01/27 17:30:34 Benzinga
TG Therapeutics Inc''s (NASDAQ: TGTX ) CEO Michael Weiss said that the FDA has placed a partial clinical hold on some combination candidate studies for leukemia and lymphoma. Speaking at the B. Riley Securities'' 2022 Virtual Oncology Investor Conference, Weiss disclosed that FDA placed partial holds on studies of the U2 combination UKONIQ … Full story available on Benzinga.com
Hot Stock to Observe: TG Therapeutics, Inc. (NASDAQ:TGTX), Oragenics, Inc. (AMEX:OGEN) 2021/07/07 00:15:19 Stock Equity
TG Therapeutics, Inc. (TGTX) with the stream of -2.92% also noticed, India Oragenics, Inc. (OGEN) encountered a rapid change of -1.76% in the last hour of Tuesdays trading session. TG The post Hot Stock to Observe: TG Therapeutics, Inc. (NASDAQ:TGTX), Oragenics, Inc. (AMEX:OGEN) appeared first on Stocks Equity .
Stock on the Move: Dave & Busters Entertainment, Inc. (NASDAQ:PLAY), TG Therapeutics, Inc. (NASDAQ:TGTX) 2021/06/28 23:27:09 Stock Equity
Dave & Busters Entertainment, Inc. (NASDAQ:PLAY) with the stream of -2.21% also noticed, India TG Therapeutics, Inc. (NASDAQ:TGTX) encountered a rapid change of -1.12% in the last hour of MONDAYs The post Stock on the Move: Dave & Busters Entertainment, Inc. (NASDAQ:PLAY), TG Therapeutics, Inc. (NASDAQ:TGTX) appeared first on Stocks Equity .
Up to Date Stock in Review: TG Therapeutics, Inc. (NASDAQ:TGTX), AgEagle Aerial Systems, Inc. (AMEX:UAVS) 2021/06/27 23:39:13 Stock Equity
TG Therapeutics, Inc. (TGTX) with the stream of 2.78% also noticed, India AgEagle Aerial Systems, Inc. (UAVS) encountered a rapid change of 0.19% in the last hour of trading session. The post Up to Date Stock in Review: TG Therapeutics, Inc. (NASDAQ:TGTX), AgEagle Aerial Systems, Inc. (AMEX:UAVS) appeared first on Stocks Equity .
Stock Views And Recommendations: TG Therapeutics, Inc. (NASDAQ:TGTX), Senseonics Holdings, Inc. (AMEX:SENS) 2021/06/23 22:24:37 Stock Equity
TG Therapeutics, Inc. (TGTX) with the stream of 0.59% also noticed, India Senseonics Holdings, Inc. (SENS) encountered a rapid change of 1.58% in the last hour of Wednesdays trading session. The post Stock Views And Recommendations: TG Therapeutics, Inc. (NASDAQ:TGTX), Senseonics Holdings, Inc. (AMEX:SENS) appeared first on Stocks Equity .
Looking Into TG Therapeutics''s Return On Capital Employed 2021/06/23 14:48:30 Benzinga
During Q1, TG Therapeutics ''s (NASDAQ: TGTX ) reported sales totaled $793.00 thousand. Despite a 2.07% in earnings, the company posted a loss of $88.73 million. In Q4, TG Therapeutics brought in $38.00 thousand in sales but lost $86.93 million in earnings. What Is ROCE? Changes in earnings and sales indicate shifts in TG Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com